Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin

American Journal of Health-System Pharmacy

Volumn 66, Issue 9, 2009, Pages 838-842

  Vets, Eva ^a   Rossignol, Jean Francois ^a,b   Jackson, Anthony Shane ^a,b,c  

^a AZ Stuivenberg   (Belgium)

^b Romark Laboratories LC   (United States)

^c Romark Laboratories   (United States)

Author keywords

Anticoagulants; Antiinfective agents; Drug interactions; Nitazoxanide; Pharmacodynamics; Pharmacokinetics; Toxicity; Warfarin sodium

Indexed keywords

BILIRUBIN; NITAZOXANIDE; WARFARIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG TOLERABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 66149184326     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080332     Document Type: Article

References (16)

1. Alinia (nitazoxanide) package insert. Tampa, FL: Romark Laboratories, L.C.; 2005 Jun.
2. Sisson G, Goodwin A, Raudonikiene A et al. Identification of enzymes associated with the reductive activation of nitazoxanide, nitrofurans and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2116-23.
3. Hoffman PS, Sisson G, Croxen MA et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007; 51:868-76.
4. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol. 2008; 3:539-45.
5. Musher DM, Logan N, Bressler AM et al. Nitazoxanide (NTZ) vs. vancomycin (VNC) in the treatment of Clostridium difficile disease (CDD); a randomized, double-blind study. Clin Infect Dis. 2009; 48:e41-6.
6. Musher DM, Logan N, Hamill RJ et al. Nitazoxanide in Clostridium difficile colitis. Clin Infect Dis. 2006; 43:421-7.
7. Hecht DW, Galang MA, Sambol S et al. In vitro activity of fifteen antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983-2004. Antimicrob Agents Chemother. 2007;51:2716-9.
8. Yamamoto Y, Hakki A, Friedman H et al. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an xnXi-Helicobacter pylori agent with anti-vacuolating toxin activity. Chemotherapy. 1999;45:303-12.
9. Guttner Y, Windsor HM, Viiala CH et al. Nitazoxanide in the treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother. 2003; 47:3780-3.
10. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug to eradicate Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother. 1998; 42:2836-40.
11. Stuppy W. Nitazoxanide and the treatment of Helicobacter pylori. Am ] Gastroenterol. 2007; 102(suppl 2):S403. Abstract.
12. Dubreuil L, Houcke X, Mouton Y et al. In vitro evaluation of the activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother. 1996; 40:2266-70.
13. Pankuch GA, Appelbaum PC, Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob Agents Chemother. 2006; 50:1112-7.
14. Zhou H, Patat A, Parks V et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004,44:543-50.
15. Jiang X, Williams KM, Liauw WS et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br } Clin Pharmacol. 2004; 57:592-9.
16. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol. 2004; 58:433-6.